Single drug treatment with the small molecule ALK/MET inhibitor crizotinib has shown very promising results in adult non-small cell lung cancer and in large cell anaplastic lymphoma that harbour ALK translocations16. The gene discussed is ALK; the disease is non-small cell lung carcinoma.